Nonfasting @entity1674 and risk of XXXX in the general population.

@entity1 @entity1674 @entity412 @entity741 @entity165 @entity385
CONTEXT: The role of @entity1674 in the risk of @entity385 remains controversial. Recently, a strong association was found between elevated levels of nonfasting @entity1674 , which indicate the presence of remnant lipoproteins, and increased risk of @entity741 . OBJECTIVE: To test the hypothesis that increased levels of nonfasting @entity1674 are associated with @entity385 in the general population. DESIGN, SETTING, AND @entity1 : The Copenhagen City Heart Study, a prospective, Danish population-based cohort study initiated in 1976, with follow-up through July 2007. @entity1 were 13,956 @entity1 and @entity1 aged 20 through 93 years. A cross-sectional study included 9637 individuals attending the 1991-1994 examination of the prospective study. MAIN OUTCOME MEASURES: Prospective study: baseline levels of nonfasting @entity1674 , other risk factors at baseline and at follow-up examinations, and incidence of @entity385 . Cross-sectional study: levels of nonfasting @entity1674 , levels of remnant @entity165 , and prevalence of @entity385 . RESULTS: Of the 13,956 @entity1 in the prospective study, 1529 developed @entity385 . Cumulative incidence of @entity385 increased with increasing levels of nonfasting @entity1674 (log-rank trend, P < .001). @entity1 with elevated nonfasting @entity412 levels of 89 through 176 mg/dL had multivariate-adjusted hazard ratios (HRs) for @entity385 of 1.3 (95% CI, 0.8-1.9; 351 events); for 177 through 265 mg/dL, 1.6 (95% CI, 1.0-2.5; 189 events); for 266 through 353 mg/dL, 1.5 (95% CI, 0.9-2.7; 73 events); for 354 through 442 mg/dL, 2.2 (95% CI, 1.1-4.2; 40 events); and for 443 mg/dL or greater, 2.5 (95% CI, 1.3-4.8; 41 events) vs @entity1 with nonfasting levels less than 89 mg/dL (HR, 1.0; 85 events) (P < .001 for trend). Corresponding values for @entity1 were 1.3 (95% CI, 0.9-1.7; 407 events), 2.0 (95% CI, 1.3-2.9; 135 events), 1.4 (95% CI, 0.7-2.9; 26 events), 2.5 (95% CI, 1.0-6.4; 13 events), and 3.8 (95% CI, 1.3-11; 10 events) vs @entity1 with nonfasting @entity412 levels less than 89 mg/dL (HR, 1.0; 159 events) (P < .001 for trend). Absolute 10-year risk of @entity385 ranged from 2.6% in @entity1 younger than 55 years with nonfasting @entity412 levels of less than 89 mg/dL to 16.7% in @entity1 aged 55 years or older with levels of 443 mg/dL or greater. Corresponding values in @entity1 were 1.9% and 12.2%. In the cross-sectional study, @entity1 with a previous @entity385 vs controls had nonfasting @entity412 levels of 191 (IQR, 131-259) mg/dL vs 148 (IQR, 104-214) mg/dL (P < .01); corresponding values for @entity1 were 167 (IQR, 121-229) mg/dL vs 127 (IQR, 91-181) mg/dL (P < .05). For remnant @entity165 , corresponding values were 38 (IQR, 26-51) mg/dL vs 29 (IQR, 20-42) mg/dL in @entity1 (P < .01) and 33 (IQR, 24-45) mg/dL vs 25 (IQR, 18-35) mg/dL in @entity1 (P < .05). CONCLUSION: In this study population, nonfasting @entity412 levels were associated with risk of @entity385 .
